Search results
Results from the WOW.Com Content Network
Nintedanib is used for the treatment of idiopathic pulmonary fibrosis. [9] It has been shown to slow down decrease in forced vital capacity, [10] [11] and it also improves people's quality of life. [12] Nintedanib does not improve survival in people with IPF. [13]
[3] [12] A recent study from the US estimated the incidence of IPF to be between 6.8 and 16.3 per 100,000 persons. In the 27 European Union countries, a range of sources estimate an incidence of 4.6–7.4 people per 100,000 of the population, [ 73 ] [ 74 ] suggesting that approximately 30,000–35,000 new patients will be diagnosed with IPF ...
1.3 Clinical studies The clinical efficacy and safety of nintedanib in IPF has been established in 1,231 patients with IPF in one Phase II clinical trial (TOMORROW) and two replicate Phase III clinical trials, INPULSIS®-1 and -2.[18][21] These were double blind, randomised and placebo-controlled trialscomparing treatment with nintedanib 150 mg ...
A Mexican restaurant in San Francisco’s Mission District, La Vaca Birria is catching attention after raising the price of its signature burrito from $11 to $22, a move that owner Ricardo Lopez ...
Patients with idiopathic pulmonary fibrosis were randomly assigned to treatment with oral pirfenidone or placebo for a minimum of 72 weeks. [47] In study 004, pirfenidone reduced decline in forced vital capacity. Mean change in FVC at week 72 was –8.0% in the pirfenidone 2403 mg/day group and –12.4% in the placebo group, a difference of 4.4%.
Since the medical term for conditions of unknown cause is "idiopathic", the clinical term for UIP of unknown cause is idiopathic pulmonary fibrosis (IPF). [2] Examples of known causes of UIP include connective tissue diseases (primarily rheumatoid arthritis ), drug toxicity, chronic hypersensitivity pneumonitis , asbestosis and Hermansky ...
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany.
The children received selumetinib 25 mg/m 2 orally twice a day until disease progression or until they experienced unacceptable adverse reactions. [ 14 ] [ 22 ] The clinical trial measured the overall response rate (ORR), defined as the percentage of subjects with a complete response and those who experienced more than a 20% reduction in PN ...